NCT00135200 · OUTCOME

Duration of Response

Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma · Source last updated 2025-04-30

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: up to approximately 15 years after treatment

What was measured

Progressive Disease (PD)-Free Interval (Duration of Response): measured, in a responder, from the date when a Complete Response, Complete Response, unconfirmed (CRu), or Partial Response (PR) is first noted to the first date at which progressive disease is observed. An ongoing PD-free interval occurs when there is a responder for whom progressive disease has not been noted.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denom Units Selected: Participants
description: Progressive Disease (PD)-Free Interval (Duration of Response): measured, in a responder, from the date when a Complete Response, Complete Response, unconfirmed (CRu), or Partial Response (PR) is first noted to the first date at which progressive disease is observed. An ongoing PD-free interval occurs when there is a responder for whom progressive disease has not been noted.
reporting Status: NOT_POSTED
time Frame: up to approximately 15 years after treatment
title: Duration of Response
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice